Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial
Abstract Background We aimed to evaluate the efficacy and safety of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin, and capecitabine) in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who failed to PD-1 i...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12916-025-03985-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849774460435955712 |
|---|---|
| author | Yaofei Jiang Weixin Bei Lin Wang Nian Lu Cheng Xu Hu Liang Liangru Ke Yanfang Ye Shuiqing He Shuhui Dong Qin Liu Chuanrun Zhang Xuguang Wang Weixiong Xia Chong Zhao Ying Huang Yanqun Xiang Guoying Liu |
| author_facet | Yaofei Jiang Weixin Bei Lin Wang Nian Lu Cheng Xu Hu Liang Liangru Ke Yanfang Ye Shuiqing He Shuhui Dong Qin Liu Chuanrun Zhang Xuguang Wang Weixiong Xia Chong Zhao Ying Huang Yanqun Xiang Guoying Liu |
| author_sort | Yaofei Jiang |
| collection | DOAJ |
| description | Abstract Background We aimed to evaluate the efficacy and safety of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin, and capecitabine) in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who failed to PD-1 inhibitor-containing regimens. Methods In this single-arm, open-label, phase 2 study, RM-NPC patients who failed to at least one line of systemic chemotherapy and anti-PD-1 immunotherapy were enrolled and received cadonilimab plus TPC chemotherapy every 3 weeks for up to 6 cycles, followed by cadonilimab plus capecitabine every 3 weeks for a maximum of 2 years. The primary endpoint was the objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DoR), and safety. Results Twenty-five patients were enrolled (84% male; median age 44 years (range, 24–60)), with a median follow-up of 10.2 months. The ORR was 68%, with 3 complete responses, 14 partial responses, and 6 stable diseases. The median DoR was 9.1 months (95% CI, 3.8–14.5 months). The median PFS was 10.6 months (95% CI, 5.2–16.0 months). The 12-month OS was 75.6%. Treatment was well tolerated. Grade 3 or 4 treatment-related adverse events occurred in 12 (48%) patients. Fourteen patients (56%) experienced potentially immune-related adverse events (irAEs). One patient experienced a grade 3 immune-related rash and another patient had grade 3 immune-related lipase increased. No treatment-related death occurred. Conclusions Cadonilimab in combination with TPC chemotherapy demonstrated promising antitumoral efficacy and manageable toxicities in patients with RM-NPC who failed frontline immunotherapy. Further trials are warranted to confirm and expand these findings. Trial registration This trial was registered at chictr.org.cn (ChiCTR2200067057). |
| format | Article |
| id | doaj-art-8e7963180c2c45e39af350ecb57f2d8d |
| institution | DOAJ |
| issn | 1741-7015 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Medicine |
| spelling | doaj-art-8e7963180c2c45e39af350ecb57f2d8d2025-08-20T03:01:41ZengBMCBMC Medicine1741-70152025-03-0123111110.1186/s12916-025-03985-4Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trialYaofei Jiang0Weixin Bei1Lin Wang2Nian Lu3Cheng Xu4Hu Liang5Liangru Ke6Yanfang Ye7Shuiqing He8Shuhui Dong9Qin Liu10Chuanrun Zhang11Xuguang Wang12Weixiong Xia13Chong Zhao14Ying Huang15Yanqun Xiang16Guoying Liu17Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Radiotherapy, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Radiology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterClinical Research Design Division, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen UniversityDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Radiotherapy, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterDepartment of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer CenterGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen UniversityAbstract Background We aimed to evaluate the efficacy and safety of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin, and capecitabine) in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who failed to PD-1 inhibitor-containing regimens. Methods In this single-arm, open-label, phase 2 study, RM-NPC patients who failed to at least one line of systemic chemotherapy and anti-PD-1 immunotherapy were enrolled and received cadonilimab plus TPC chemotherapy every 3 weeks for up to 6 cycles, followed by cadonilimab plus capecitabine every 3 weeks for a maximum of 2 years. The primary endpoint was the objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DoR), and safety. Results Twenty-five patients were enrolled (84% male; median age 44 years (range, 24–60)), with a median follow-up of 10.2 months. The ORR was 68%, with 3 complete responses, 14 partial responses, and 6 stable diseases. The median DoR was 9.1 months (95% CI, 3.8–14.5 months). The median PFS was 10.6 months (95% CI, 5.2–16.0 months). The 12-month OS was 75.6%. Treatment was well tolerated. Grade 3 or 4 treatment-related adverse events occurred in 12 (48%) patients. Fourteen patients (56%) experienced potentially immune-related adverse events (irAEs). One patient experienced a grade 3 immune-related rash and another patient had grade 3 immune-related lipase increased. No treatment-related death occurred. Conclusions Cadonilimab in combination with TPC chemotherapy demonstrated promising antitumoral efficacy and manageable toxicities in patients with RM-NPC who failed frontline immunotherapy. Further trials are warranted to confirm and expand these findings. Trial registration This trial was registered at chictr.org.cn (ChiCTR2200067057).https://doi.org/10.1186/s12916-025-03985-4CadonilimabPD-1/CTLA-4 bispecificNasopharyngeal carcinomaImmunotherapy rechallenge |
| spellingShingle | Yaofei Jiang Weixin Bei Lin Wang Nian Lu Cheng Xu Hu Liang Liangru Ke Yanfang Ye Shuiqing He Shuhui Dong Qin Liu Chuanrun Zhang Xuguang Wang Weixiong Xia Chong Zhao Ying Huang Yanqun Xiang Guoying Liu Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial BMC Medicine Cadonilimab PD-1/CTLA-4 bispecific Nasopharyngeal carcinoma Immunotherapy rechallenge |
| title | Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial |
| title_full | Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial |
| title_fullStr | Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial |
| title_full_unstemmed | Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial |
| title_short | Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial |
| title_sort | efficacy and safety of cadonilimab pd 1 ctla 4 bispecific in combination with chemotherapy in anti pd 1 resistant recurrent or metastatic nasopharyngeal carcinoma a single arm open label phase 2 trial |
| topic | Cadonilimab PD-1/CTLA-4 bispecific Nasopharyngeal carcinoma Immunotherapy rechallenge |
| url | https://doi.org/10.1186/s12916-025-03985-4 |
| work_keys_str_mv | AT yaofeijiang efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT weixinbei efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT linwang efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT nianlu efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT chengxu efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT huliang efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT liangruke efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT yanfangye efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT shuiqinghe efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT shuhuidong efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT qinliu efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT chuanrunzhang efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT xuguangwang efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT weixiongxia efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT chongzhao efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT yinghuang efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT yanqunxiang efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial AT guoyingliu efficacyandsafetyofcadonilimabpd1ctla4bispecificincombinationwithchemotherapyinantipd1resistantrecurrentormetastaticnasopharyngealcarcinomaasinglearmopenlabelphase2trial |